Feature ArticlesCE Cardiotoxicity and Breast Cancer as Late Effects of Pediatric and Adolescent Hodgkin Lymphoma TreatmentCandela, Joanne Lee MPH, ANP Author Information Joanne Lee Candela is an adult NP in the survivorship program at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. Contact author: [email protected]. The author acknowledges Bridgette Thom, MS, research specialist at the MSKCC, for her thoughtful suggestions regarding the manuscript. The author and planners have disclosed no potential conflicts of interest, financial or otherwise. AJN, American Journal of Nursing 116(4):p 32-42, April 2016. | DOI: 10.1097/01.NAJ.0000482143.27671.36 Buy SDC CE Test Metrics AbstractIn Brief The American Cancer Society estimates that in 2014 nearly 16,000 U.S. children and adolescents developed cancer, and in roughly 1,200 of these cases the cancer was Hodgkin lymphoma (HL). The great majority of these patients will survive, joining the thousands who have been diagnosed and treated successfully in decades past. Nurses’ familiarity with and attention to the late effects of the chemotherapy and radiation therapy used to treat HL, which include breast cancer as well as cardiotoxicity and its sequelae, are essential in helping these patients maintain their overall health. The author of this second article in a series on cancer survivorship care from Memorial Sloan Kettering Cancer Center reviews the late adverse effects associated with the management of Hodgkin lymphoma. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
